Logo image of IRD

OPUS GENETICS INC (IRD) Stock Fundamental Analysis

NASDAQ:IRD - US67577R1023 - Common Stock

1.27 USD
-0.01 (-0.78%)
Last: 9/5/2025, 8:22:59 PM
1.31 USD
+0.04 (+3.15%)
Pre-Market: 9/8/2025, 6:08:02 AM
Fundamental Rating

2

Taking everything into account, IRD scores 2 out of 10 in our fundamental rating. IRD was compared to 541 industry peers in the Biotechnology industry. Both the profitability and financial health of IRD have multiple concerns. IRD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IRD has reported negative net income.
IRD had a negative operating cash flow in the past year.
IRD had negative earnings in 4 of the past 5 years.
IRD had negative operating cash flow in 4 of the past 5 years.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

The Return On Assets of IRD (-150.72%) is worse than 85.58% of its industry peers.
Looking at the Return On Equity, with a value of -333.51%, IRD is doing worse than 72.83% of the companies in the same industry.
Industry RankSector Rank
ROA -150.72%
ROE -333.51%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

IRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IRD has been increased compared to 5 years ago.
There is no outstanding debt for IRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

IRD has an Altman-Z score of -5.31. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IRD (-5.31) is worse than 61.92% of its industry peers.
IRD has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IRD (0.06) is worse than 61.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -5.31
ROIC/WACCN/A
WACC9.65%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

IRD has a Current Ratio of 1.90. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
IRD has a Current ratio of 1.90. This is in the lower half of the industry: IRD underperforms 76.71% of its industry peers.
IRD has a Quick Ratio of 1.90. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
IRD's Quick ratio of 1.90 is on the low side compared to the rest of the industry. IRD is outperformed by 75.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for IRD have decreased strongly by -58.18% in the last year.
IRD shows a decrease in Revenue. In the last year, the revenue decreased by -6.28%.
The Revenue has been growing by 165.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-6.28%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%159.17%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
Based on estimates for the next years, IRD will show a very strong growth in Revenue. The Revenue will grow by 33.33% on average per year.
EPS Next Y40.01%
EPS Next 2Y27.69%
EPS Next 3Y15.5%
EPS Next 5Y14.87%
Revenue Next Year61.29%
Revenue Next 2Y74.86%
Revenue Next 3Y30.19%
Revenue Next 5Y33.33%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IRD's earnings are expected to grow with 15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.69%
EPS Next 3Y15.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPUS GENETICS INC

NASDAQ:IRD (9/5/2025, 8:22:59 PM)

Premarket: 1.31 +0.04 (+3.15%)

1.27

-0.01 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10
Inst Owners17.03%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner Change67.88%
Market Cap80.07M
Analysts80
Price Target8.16 (542.52%)
Short Float %0.39%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.5%
Min EPS beat(2)4.95%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)10.31%
Min EPS beat(4)-20.9%
Max EPS beat(4)42.04%
EPS beat(8)4
Avg EPS beat(8)-21.76%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)9
Avg EPS beat(16)-8.54%
Revenue beat(2)1
Avg Revenue beat(2)5.08%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)39.62%
Revenue beat(4)3
Avg Revenue beat(4)29.95%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)67.33%
Revenue beat(8)4
Avg Revenue beat(8)28.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.56%
PT rev (3m)-5.88%
EPS NQ rev (1m)36.9%
EPS NQ rev (3m)47%
EPS NY rev (1m)22.84%
EPS NY rev (3m)27.41%
Revenue NQ rev (1m)-18.24%
Revenue NQ rev (3m)-15.47%
Revenue NY rev (1m)-13.45%
Revenue NY rev (3m)-11.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 4.58
P/tB 4.58
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.24
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -150.72%
ROE -333.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -5.31
F-Score2
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y40.01%
EPS Next 2Y27.69%
EPS Next 3Y15.5%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-6.28%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%159.17%
Revenue Next Year61.29%
Revenue Next 2Y74.86%
Revenue Next 3Y30.19%
Revenue Next 5Y33.33%
EBIT growth 1Y-152.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-247.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-247.16%
OCF growth 3YN/A
OCF growth 5YN/A